Drs Brian Helfand and Steven Finkelstein share key takeaways and clinical pearls from the phase 2/3 EMPIRE-1 trial for prostate cancer.
Brian Helfand, MD, PhD, NorthShore University
Advertisement
Articles by Brian Helfand, MD, PhD, NorthShore University
Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, review results from the phase 2/3 EMPIRE-1 trial examining the use of ¹⁸F-fluciclovine-PET/CT imaging to guide postprostatectomy salvage radiotherapy for prostate cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
3
An Oncodermatologist’s Perspective on Dermatological Toxicities in Breast Cancer
4
What Path to Approval Has Dasatinib Taken in CML/ALL?
5
